Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02526017
Title Study of FPA008 in Combination With Nivolumab in Patients With Selected Advance Cancers
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Five Prime Therapeutics, Inc.
Indications

melanoma

colorectal cancer

pancreatic cancer

lung non-small cell carcinoma

head and neck squamous cell carcinoma

glioblastoma

Therapies

Cabiralizumab

Nivolumab

Age Groups: adult
Covered Countries USA


No variant requirements are available.